HomeProductsBuilding BlocksFunctional GroupsPhosphorus CompoundsTenofovir Disoproxil
Chemical structure of CAS 201341-05-1

Tenofovir Disoproxil

In Stock•Starting at $14 for 1 g•Purity ≥ 98%
CAS No.201341-05-1
MDL No.MFCD00952920
MFC19H30N5O10P
MW519.40
InChI KeyJFVZFKDSXNQEJW-CQSZACIVSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 g98%$14In Stock
5 g98%$39In Stock
25 g98%$126In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Tenofovir disoproxil is an organic phosphonate and the disoproxil ester of tenofovir. It serves as a prodrug for tenofovir, an HIV-1 reverse transcriptase inhibitor. Used as the fumaric acid salt in combination therapy for HIV treatment, it functions as a prodrug, HIV-1 reverse transcriptase inhibitor, and antiviral drug. It is functionally related to tenofovir (anhydrous).

CAS No.201341-05-1
Product NameTenofovir Disoproxil

Associated Conditions

primary biliary cirrhosis·chronic hepatitis·infection·HIV infection·Parkinson disease·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Antimicrobial agents and chemotherapy • Vol. 51, Issue 8 • 2007
PMID: 17548498PMC: PMC1932487DOI: 10.1128/AAC.00277-07

Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses.

Arzneimittel-Forschung • Vol. 56, Issue 2A • 2006
PMID: 16570827DOI: 10.1055/s-0031-1296806

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.

Antimicrobial agents and chemotherapy • Vol. 50, Issue 7 • 2006
PMID: 16801428PMC: PMC1489769DOI: 10.1128/AAC.00138-06

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • Vol. 41, Issue 2 • 2005
PMID: 15983922DOI: 10.1086/430709

Documentation

Similar Products